Intra-Prostate Cancer Vaccine Inducer
Annual rept. 26 Jan 2005-25 Jan 2006
ANTIGEN EXPRESS INC WORCESTER MA
Pagination or Media Count:
A large amount of effort has been focused on the optimization of human Ii-RNAi constructs during the past year. We have optimized the use of a combination of human Ii-RNAi constructs, which target different sites of Ii mRNA, to obtain optimal Ii suppression. More importantly, we have defined the influence of the promoter on the activity of Ii-RNAi. Our results indicate that two elements are important for the activity of an Ii-RNAi construct a selection of the correct Ii-RNAi sequence that targets a specific location on Ii mRNA and, b selection of the best promoter that is active in that cell line. We have defined three active Ii-RNAi constructs and tested their activity of three different promoters, U6, CMV, and EF-1a. Each is active in different types of cells. Lastly, we have tested the activity of our Ii-RNAi constructs in fresh tumor cells. Concurrently, the task of optimization of the doses of IL-2 and IFN- is being addressed and optimized with our collaborator, Dr. Hillman. Substantial progress has been made in the optimization of Ii-RNAi constructs. We will continue our effort to pick the most active human Ii- RNAi constructs for prostate cancer clinical trial.
- Medicine and Medical Research